AR068794A1 - Compuestos antivirales - Google Patents
Compuestos antiviralesInfo
- Publication number
- AR068794A1 AR068794A1 ARP080102758A ARP080102758A AR068794A1 AR 068794 A1 AR068794 A1 AR 068794A1 AR P080102758 A ARP080102758 A AR P080102758A AR P080102758 A ARP080102758 A AR P080102758A AR 068794 A1 AR068794 A1 AR 068794A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkynyl
- alkenyl
- och2p
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 11
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001589 carboacyl group Chemical group 0.000 abstract 4
- -1 carboxy, hydroxy Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241001024304 Mino Species 0.000 abstract 1
- 101800001098 Serine protease NS3 Proteins 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 125000005505 thiomorpholino group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93775207P | 2007-06-29 | 2007-06-29 | |
| US95969807P | 2007-07-16 | 2007-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068794A1 true AR068794A1 (es) | 2009-12-09 |
Family
ID=40202103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102758A AR068794A1 (es) | 2007-06-29 | 2008-06-26 | Compuestos antivirales |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8513186B2 (https=) |
| EP (1) | EP2162432A2 (https=) |
| JP (2) | JP5465667B2 (https=) |
| KR (1) | KR20100038417A (https=) |
| CN (1) | CN101801925A (https=) |
| AP (1) | AP2009005073A0 (https=) |
| AR (1) | AR068794A1 (https=) |
| AU (1) | AU2008271117B2 (https=) |
| BR (1) | BRPI0813733A2 (https=) |
| CA (1) | CA2692145C (https=) |
| CO (1) | CO6251241A2 (https=) |
| EA (1) | EA200971074A1 (https=) |
| EC (1) | ECSP109906A (https=) |
| IL (1) | IL202623A0 (https=) |
| MX (1) | MX2009013830A (https=) |
| SG (1) | SG182979A1 (https=) |
| TW (1) | TW200914013A (https=) |
| WO (1) | WO2009005677A2 (https=) |
| ZA (1) | ZA201000614B (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| ES2437147T3 (es) * | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Inhibidores de serina proteasa macrocíclicos |
| US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| PE20110343A1 (es) | 2008-09-17 | 2011-06-25 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina |
| JP2012502925A (ja) * | 2008-09-23 | 2012-02-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
| KR20110114582A (ko) * | 2008-12-19 | 2011-10-19 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｃｖ ｎｓ３ 프로테아제 억제제 |
| JP2012516351A (ja) * | 2009-01-30 | 2012-07-19 | アナコール ファーマシューティカルズ，インコーポレーテッド | 化合物 |
| JP2012520891A (ja) * | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホニルキノリンの製造方法 |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| WO2010122682A1 (ja) | 2009-04-24 | 2010-10-28 | 株式会社カネカ | Ｎ－アルコキシカルボニル－ｔｅｒｔ－ロイシンの製造法 |
| US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| UY32826A (es) | 2009-08-04 | 2011-02-28 | Takeda Pharmaceutical | Compuestos heterocíclicos |
| EP2461811B1 (en) | 2009-08-05 | 2016-04-20 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| CN102741270B (zh) * | 2009-09-28 | 2015-07-22 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| MX2012003171A (es) * | 2009-09-28 | 2012-04-11 | Hoffmann La Roche | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| EP2504342A1 (en) | 2009-11-23 | 2012-10-03 | Pfizer Inc. | Imidazo-pyrazoles as gpr119 inhibitors |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| KR101492351B1 (ko) * | 2010-09-22 | 2015-02-10 | 미쓰이가가쿠 아그로 가부시키가이샤 | 함불소 카바메이트기를 가지는 아미노산 아미드 유도체의 제조방법, 그 제조 중간체, 및 에틸렌디아민 유도체의 제조방법 |
| WO2012047764A1 (en) * | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Therapeutic antiviral peptides |
| AU2011349844B2 (en) | 2010-12-20 | 2017-06-01 | Gilead Sciences, Inc. | Combinations for treating HCV |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
| EP4556010A3 (en) | 2011-11-30 | 2025-07-23 | Emory University | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| EP2903988A1 (en) | 2012-10-08 | 2015-08-12 | AbbVie Inc. | Compounds useful for making hcv protease inhibitors |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN102937580B (zh) * | 2012-11-02 | 2015-09-02 | 天津科技大学 | 食用油脂中缩水甘油酯的检测方法 |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CA2897268C (en) * | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| PT2950786T (pt) | 2013-01-31 | 2020-03-03 | Gilead Pharmasset Llc | Formulação de combinação de dois compostos antivirais |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| KR20150131244A (ko) * | 2013-03-13 | 2015-11-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스테이플드 및 스티치드 폴리펩티드 및 그의 용도 |
| US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
| PE20160655A1 (es) | 2013-07-11 | 2016-07-08 | Evestra Inc | Profarmacos de formacion de compuestos |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| CN105504007B (zh) * | 2014-10-14 | 2021-03-16 | 中国药科大学 | 氨基磷酸酯衍生物、其制备方法及其在制药中的用途 |
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109414508A (zh) | 2016-05-27 | 2019-03-01 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| US9957233B1 (en) | 2016-08-05 | 2018-05-01 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| US10624903B2 (en) | 2017-10-19 | 2020-04-21 | Evestra, Inc. | Longer-acting progestin prodrug contraceptives |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| CN114149353B (zh) * | 2019-11-22 | 2024-05-17 | 华东师范大学 | 一类n-烷基/n-芳基硫代酰胺衍生物及其合成方法和应用 |
| TWI854067B (zh) | 2019-11-26 | 2024-09-01 | 美商基利科學股份有限公司 | 預防hiv之蛋白殼抑制劑 |
| PL4172157T3 (pl) | 2020-06-25 | 2026-03-23 | Gilead Sciences, Inc. | Inhibitory kapsydu w leczeniu hiv |
| KR20230062845A (ko) * | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| CN112961106A (zh) * | 2021-03-13 | 2021-06-15 | 德州学院 | 一种4-羟基-6氯喹啉合成新工艺 |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| DK4445900T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| US5500208A (en) | 1994-06-07 | 1996-03-19 | The Procter & Gamble Company | Oral compositions comprising a novel tripeptide |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
| US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| EP0907659A1 (en) | 1996-05-10 | 1999-04-14 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
| AP1019A (en) | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
| ES2241157T3 (es) | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
| DK1066247T3 (da) | 1998-03-31 | 2007-04-02 | Vertex Pharma | Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| AU756627B2 (en) | 1998-07-27 | 2003-01-16 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Diketoacid-derivatives as inhibitors of polymerases |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| ID27787A (id) | 1998-08-21 | 2001-04-26 | Viro Pharma Inc | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan |
| BR9913406A (pt) | 1998-09-04 | 2002-01-29 | Viropharma Inc | Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção |
| KR20010079907A (ko) | 1998-09-25 | 2001-08-22 | 비로파마 인코포레이티드 | 바이러스 감염 및 관련 질병의 치료 및 예방 방법 |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| EP1162196A4 (en) | 1999-12-27 | 2003-04-16 | Japan Tobacco Inc | COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS |
| US20040034041A1 (en) | 2000-05-10 | 2004-02-19 | Dashyant Dhanak | Novel anti-infectives |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| ES2263687T3 (es) | 2000-11-20 | 2006-12-16 | Bristol-Myers Squibb Company | Inhibidores tripeptidicos de la hepatitis c. |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
| ES2361011T3 (es) | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| DE60324552D1 (en) | 2002-05-20 | 2008-12-18 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
| CA2515216A1 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
| WO2004101605A1 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| JP4231524B2 (ja) | 2003-04-10 | 2009-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状化合物の製造方法 |
| ES2320771T3 (es) * | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| CN1788006A (zh) | 2003-04-18 | 2006-06-14 | 安南塔制药公司 | 喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| HRP20130098T1 (hr) * | 2003-10-14 | 2013-02-28 | F. Hoffmann - La Roche Ag | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP1730167B1 (en) * | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| BRPI0509467A (pt) | 2004-03-30 | 2007-09-11 | Intermune Inc | compostos macrocìclicos como inibidores de replicação viral |
| RS51974B (sr) * | 2004-07-16 | 2012-02-29 | Gilead Sciences Inc. | Antivirusna jedinjenja |
| JP4914355B2 (ja) | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) * | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TW200738742A (en) * | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2008
- 2008-06-26 AP AP2009005073A patent/AP2009005073A0/en unknown
- 2008-06-26 JP JP2010514802A patent/JP5465667B2/ja not_active Expired - Fee Related
- 2008-06-26 EA EA200971074A patent/EA200971074A1/ru unknown
- 2008-06-26 CN CN200880104330A patent/CN101801925A/zh active Pending
- 2008-06-26 BR BRPI0813733-1A patent/BRPI0813733A2/pt not_active IP Right Cessation
- 2008-06-26 SG SG2012048484A patent/SG182979A1/en unknown
- 2008-06-26 AU AU2008271117A patent/AU2008271117B2/en not_active Ceased
- 2008-06-26 TW TW097123925A patent/TW200914013A/zh unknown
- 2008-06-26 KR KR1020107002261A patent/KR20100038417A/ko not_active Ceased
- 2008-06-26 WO PCT/US2008/007928 patent/WO2009005677A2/en not_active Ceased
- 2008-06-26 AR ARP080102758A patent/AR068794A1/es not_active Application Discontinuation
- 2008-06-26 MX MX2009013830A patent/MX2009013830A/es not_active Application Discontinuation
- 2008-06-26 EP EP08779772A patent/EP2162432A2/en not_active Withdrawn
- 2008-06-26 US US12/215,601 patent/US8513186B2/en active Active
- 2008-06-26 CA CA2692145A patent/CA2692145C/en not_active Expired - Fee Related
-
2009
- 2009-12-09 IL IL202623A patent/IL202623A0/en unknown
- 2009-12-18 CO CO09145303A patent/CO6251241A2/es not_active Application Discontinuation
-
2010
- 2010-01-27 ZA ZA2010/00614A patent/ZA201000614B/en unknown
- 2010-01-28 EC EC2010009906A patent/ECSP109906A/es unknown
-
2013
- 2013-06-13 JP JP2013124380A patent/JP2013177452A/ja not_active Withdrawn
- 2013-07-01 US US13/932,945 patent/US8809267B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008271117B2 (en) | 2013-10-24 |
| SG182979A1 (en) | 2012-08-30 |
| CO6251241A2 (es) | 2011-02-21 |
| CA2692145C (en) | 2015-03-03 |
| WO2009005677A2 (en) | 2009-01-08 |
| BRPI0813733A2 (pt) | 2019-11-05 |
| EA200971074A1 (ru) | 2010-08-30 |
| JP5465667B2 (ja) | 2014-04-09 |
| IL202623A0 (en) | 2010-06-30 |
| EP2162432A2 (en) | 2010-03-17 |
| CN101801925A (zh) | 2010-08-11 |
| US8513186B2 (en) | 2013-08-20 |
| MX2009013830A (es) | 2010-03-01 |
| WO2009005677A3 (en) | 2009-03-05 |
| US8809267B2 (en) | 2014-08-19 |
| JP2010532352A (ja) | 2010-10-07 |
| AP2009005073A0 (en) | 2009-12-31 |
| ECSP109906A (es) | 2010-03-31 |
| US20090186869A1 (en) | 2009-07-23 |
| TW200914013A (en) | 2009-04-01 |
| US20140051626A1 (en) | 2014-02-20 |
| AU2008271117A1 (en) | 2009-01-08 |
| CA2692145A1 (en) | 2009-01-08 |
| KR20100038417A (ko) | 2010-04-14 |
| ZA201000614B (en) | 2011-11-30 |
| JP2013177452A (ja) | 2013-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068794A1 (es) | Compuestos antivirales | |
| AR067180A1 (es) | Compuestos antivirales | |
| AR061840A1 (es) | Compuestos fosfinatos antivirales | |
| AR054837A1 (es) | Compuestos inhibidores del virus de la hepatitis c | |
| AR054838A1 (es) | Compuestos inhibidores del virus de la hepatitis c | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR074474A1 (es) | Inhibidores ns5a de vhc | |
| AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
| AR074670A1 (es) | Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c | |
| PE20211504A1 (es) | Compuestos de anillo fusionado | |
| AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| AR050174A1 (es) | Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas | |
| ECSP18072109A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak campo de la invención | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| AR058025A1 (es) | Procesos de obtencion de pirroles y productos intermedios para la preparacion de inhibidores de proteasa | |
| AR084720A1 (es) | Inhibidores de anillos fusionados triciclicos de hepatitis c | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| CO5580788A2 (es) | Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| AR076164A1 (es) | Inhibidores de anillos fusionados de hepatitis c | |
| AR061629A1 (es) | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas | |
| AR060405A1 (es) | Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |